Brief: Theseus Pharmaceuticals Announces First Patient Treated With The-630 In Phase 1/2 Study In Patients With Advanced Gastrointestinal Stromal Tumors
10/01/2022 12:25
Jan 10 (Reuters) - Theseus Pharmaceuticals Inc THRX.O :
* THESEUS PHARMACEUTICALS ANNOUNCES FIRST PATIENT TREATED WITH THE-630 IN
PHASE
1/2 STUDY IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (GIST)
Source text for Eikon: ID:nPn2S2FmBa
Further company coverage: THRX.O
Recent news on Theseus Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
Theseus Pharma rises as Concentra Biosciences agrees to take it private
Brief: Theseus Pharmaceuticals To Be Acquired by Concentra Biosciences
Brief: Theseus Pharmaceuticals Inc Says As Part Of A Reduction In Workforce, Co Terminated Employment Of Timothy P. Clackson, Co's CEO, Effective As Of Dec 7